The DOI matches its Crossref record.
T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease
Abstract
Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T cell–depleted allogeneic bone marrow transplants from HLA-identical sibling donors. Patients received myeloablative cytoreduction consisting of hyperfractionated total body irradiation, thiotepa, and cyclophosphamide. Those patients at risk for immune-mediated graft rejection received additional immune suppression with antithymocyte globulin and methylprednisolone in the early peritransplant period. Patients with AML who underwent allogeneic T-cell–depleted bone marrow transplantations (BMT) in first or second remission have achieved respective disease-free survival (DFS) probabilities of 77% (median follow-up at approximately 56 months) and 50% (median follow-up at approximately 48 months). Ten of 31 patients transplanted in first remission were ≥ 40 years old and have attained a DFS at 4 years of 70%. For patients with AML transplanted in first or second remission, the respective cause-specific probabilities of relapse were 3.2% or 12.5%, and those of nonleukemic mortality were 19.4% or 37.5%. There were no cases of immune-mediated graft rejection and no cases of grade II to IV acute graft-versus-host disease (GVHD). All survivors enjoy Karnofsky performance scores (KPS) of 100%, except 2 patients with KPS of 80% to 90%. T-cell–depleted allogeneic BMT can provide durable DFS together with an excellent performance status in the majority of patients with de novo AML. In addition, GVHD is not an obligatory correlate of the graft-versus-leukemia benefit or freedom from relapse afforded by allogeneic BMT administered as postremission therapy for AML. This study provides a basis for prospective comparison with other postremission therapies considered standard in the management of patients with this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aversa, F., Terenzi, A., Tabilio, A., Falzetti, F., Carotti, A., Ballanti, S., Felicini, R., Falcinelli, F., Velardi, A., Ruggeri, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.117 · Cited by 707
Ho, V. T., & Soiffer, R. J. (2001) · Blood · doi:10.1182/blood.v98.12.3192 · Cited by 426
Haematopoietic cell transplantation as immunotherapy
Appelbaum, F. R. (2001) · Nature · doi:10.1038/35077251 · Cited by 411
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Landgren, O., Gilbert, E. S., Rizzo, J. D., Socié, G., Banks, P. M., Sobocinski, K. A., Horowitz, M. M., Jaffe, E. S., Kingma, D. W., Travis, L. B., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178046 · Cited by 400
Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Grewal, S. S., Barker, J. N., Davies, S. M., & Wagner, J. E. (2003) · Blood · doi:10.1182/blood-2002-08-2510 · Cited by 284
Metadata
- Authors
- Papadopoulos, E. B., Carabasi, M. H., Castro-Malaspina, H., Childs, B. H., Mackinnon, S., Boulad, F., Gillio, A. P., Kernan, N. A., Small, T. N., Szabolcs, P., Taylor, J., Yahalom, J., Collins, N. H., Bleau, S. A., Black, P. M., Heller, G., Reilly, R. J. O., & Young, J. W.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-02-01
- Volume
- 91
- Issue
- 3
- Pages
- 1083-1090
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W162809425
- Cited by
- 217
- References
- 0
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. https://app.cochat.ai/papers/10.1182/blood.v91.3.1083
- The paper
- Papadopoulos, E. B., Carabasi, M. H., Castro-Malaspina, H., Childs, B. H., Mackinnon, S., Boulad, F., Gillio, A. P., Kernan, N. A., Small, T. N., Szabolcs, P., Taylor, J., Yahalom, J., Collins, N. H., Bleau, S. A., Black, P. M., Heller, G., Reilly, R. J. O., & Young, J. W. (1998). T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood. https://doi.org/10.1182/blood.v91.3.1083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.